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ABStrAct
the human genome project created the field of genom-
ics – understanding genetic material on a large scale. 
Scientists are deciphering the information held within 
the sequence of our genome. By building upon this 
knowledge, physicians and scientists will create funda-
mental new technologies to understand the contribu-
tion of genetics to diagnosis, prognosis, monitoring, 
and treatment of human disease. the science of genomic 
medicine has only begun to affect our understanding of 
health. 
IntroductIon
The human genome is made of deoxyribonucleic acids 
(DNA). DNA carries the blueprints for all cellular proteins, 
and is a linear double-helical molecule. This double-helix 
is composed of two intertwined chains of nucleotides. 
Each nucleotide is built from a deoxyribose sugar, a nitro-
gen base (adenine (A), thymine (T), guanine (G), or cyto-
sine (C)), and a phosphate. Two complementary chains of 
nucleotides are held together by weak hydrogen bonds 
between the bases A and T, or G and C. DNA molecules 
are coiled into higher order structures (e.g., chromo-
somes). In humans, DNA encodes about 25,000 protein-
coding genes. These genes comprise only 2 percent of the 
human genome. The remaining 98 percent of the DNA 
largely consists of repetitive non-coding DNA sequences, 
some of which have regulatory functions. About 99.9 
percent of the DNA is the same in all individuals. Small 
differences in DNA make each one of us unique and 
affect our responses to drugs as well as our susceptibility 
to disease. Except for germ cells, every cell of the human 
body contains two sets of 23 chromosomes, which are 
located in the cell nucleus. Each chromosome comes in 
two copies (alleles), maternal and paternal. At any given 
time, only a fraction of these genes are expressed. This 
expressed subset of genes confers unique properties to 
each cell in our bodies.
The information contained within the DNA is transcribed 
into messenger ribonucleic acids (mRNA) molecules. 
mRNA in turn is translated into the proteins that perform 
most the critical cellular functions. mRNA molecules are 
the working copies of genes. They are similar to DNA 
except that they are single stranded, have a ribose sugar 
instead of deoxyribose, and uracil (U) instead of thymine 
(T). Once a gene is transcribed and processed into mRNA, 
it leaves the nucleus and enters the cytoplasm where the 
protein synthesis machinery, ribosomes, is located. There 
the mRNA is read by the ribosomes in groups of three 
nucleotides called codons. Codons translate the nucleic 
acid code of DNA and mRNA into protein by specify-
ing the particular amino acid to be incorporated into a 
growing polypeptide chain.
This polypeptide chain folds to make a protein. Proteins 
comprise the majority of cell structures. Since the genetic 
code (i.e., DNA) ultimately determines the proteins that 
are synthesized, point mutations, polymorphisms, and 
deletions or insertions in the DNA affect the sequence 
and the amount of the proteins synthesized. Missense 
(the substitution of a different amino acid in the poly-
peptide chain), nonsense (the premature termination of 
polypeptide synthesis), and frameshift (the disruption 
of the codon reading frame by one or two nucleotides) 
mutations can alter or abolish protein function. The 
inheritance of these types of mutations is the foundation 
of genetic disease.
Genetics contributes to the formation of disease (i.e., 
single gene and multiple gene diseases), disease suscep-
tibility, differences in disease severity, and differences 
in therapeutic response. Recent scientific advances, like 
DNA microarrays, greatly facilitate the study of gene 
expression and the role of specific genes in the develop-
ment of disease. The human genome project has pro-
vided copious amounts of information about the DNA 
sequence of the human genome. Consequently, scientists 
have identified a large number of novel genes. The main 
challenge today is to analyze, organize, and catalog this 
vast amount of information. Traditional methods for 
studying gene expression allow studies of a relatively 
small number of genes at a time. The development of 
new genomic tools enables researchers to address large 
scale problems and to uncover novel potential targets 
for diagnosis, prevention, and therapy.
dnA MIcroArrAy technoloGy
DNA microarray technology allows researchers to ana-
lyze the expression of many genes in a single experi-
ment. Microarrays are small, solid supports onto which 
the sequences from thousands of genes are attached at 
independent fixed locations. The supports can be glass 
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microscope slides, nylon membranes, or silicon chips. The 
DNA is spotted (e.g., cDNA microarray) or synthesized 
(e.g., Affymetrix Gene Chip) onto the solid support. 
The gene sequences are attached to their support in an 
orderly way, which allows researchers to use the location 
of each spot in the array to identify a particular gene 
sequence. The spots themselves can be DNA, cDNA (i.e., a 
DNA sequence that complements mRNA), or oligonucle-
otides (i.e., single-stranded DNA 5 to 50 nucleotides in 
length).
DNA microarrays take advantage of the properties of 
complementarity between DNA and RNA molecules (i.e., 
A must pair with U or T, and C must pair with G, one 
strand determines the sequence of the other and the 
sequence of the mRNA, hence complementary strands 
of DNA or RNA will anneal or bind to each other). The 
ability of cDNA to hybridize to the DNA template from 
which it was transcribed is paramount.
To run a DNA microarray, mRNA is isolated from the cells 
or tissue of interest as well as the control cells or tissue. 
The mRNA is reverse transcribed into a fluorescently 
labeled cDNA (either red or green, one color for the 
experimental sample and one for the control sample). 
These fluorescently labeled cDNA probes are hybridized 
to the microarray. After washing, the expression levels of 
the thousands of genes on the microarray are analyzed 
by a scanning fluorescence laser that can measure the 
intensity of red and green at each location on the array. 
By measuring the intensity of fluorescence at each spot 
on the array and comparing the intensity to the control 
sample, one can determine the activity of a particular 
gene or groups of genes. (For an internet animation of 
this process see http://www.bio.davidson.edu/courses/
genomics/chip/chip.html.)
IMpAct of dnA MIcroArrAyS
Due to their small size and the fact that they contain a 
very large number of genes, microarrays are a significant 
advance over traditional methods for measuring gene 
expression (e.g., Southern blots). Microarrays can assay 
gene expression within a single sample or compare 
gene expression in two different cell types or tissues in 
large-scale genetic analysis. For example, microarrays 
can be used to study which genes in cells are actively 
making products under a particular set of conditions, as 
well as to detect differences in gene activity between 
healthy and diseased cells. One of the most important 
applications for arrays so far is the monitoring of gene 
expression (mRNA abundance). The collection of genes 
that are expressed or transcribed from genomic DNA, 
referred to as the expression profile (transcriptome), is a 
major determinant of cellular phenotype and function. 
Unlike the genome, the transcriptome changes rapidly 
and dramatically during normal cellular events such as 
DNA replication and cell division. In terms of understand-
ing the function of genes, knowing when, where, and 
to what extent a gene is expressed is central to under-
standing the biological roles of its encoded protein. In 
addition, changes in the patterns of gene expressions 
can provide clues about regulatory mechanisms and bio-
chemical pathways. In the context of human health, the 
knowledge gained from these types of measurements 
Microarray Type   Application
Gene Expression  Drug and Therapy Development
  Prognosis Prediction
  Genetic Testing
Comparative Genomic Hybridization Tumor Classification
  Risk Assessment
  Prognosis Prediction
  Genetic Testing
Single Nucleotide Polymorphisms Drug and Therapy Development
  Prognosis Prediction
  Genetic testing
TABLE 1 I DNA MICROARRAY APPLICATIONS
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may determine the source and outcome of a disease and 
identify gene products with therapeutic utility or targets 
for therapeutic intervention (Friend et al., 2002).
Microarrays are also used for studies of genomic gains 
and losses (i.e., Comparative Genomic Hybridization 
microarray), and DNA mutations (i.e., SNPs microarrays) 
(Friend and Stoughton, 2002) (Table 1). Changes in chro-
mosomal DNA, such as mutations, genetic rearrange-
ments, and amplifications or losses of particular chromo-
somal regions can often lead to abnormalities, such as 
Down’s or Turner’s syndrome. Comparisons of the copy 
number of genomic regions or the genotype of genetic 
markers may be used to detect chromosomal regions and 
genes that are amplified or lost in different cell types 
including cancerous and pre-cancerous cells. By applying 
arrays, scientists can identify when and where changes 
in copy number, chromosomal rearrangements, and DNA 
mutations have occurred. These changes can be used for 
diagnosis of developmental disorders (Dobrovolski et al., 
1999), identification of tumor-suppressor genes, disease 
prognosis, and treatment selection.
Despite its impressive potential, microarray technology 
requires improvement, innovation, and increased acces-
sibility. Nucleic acid array-based experiments are becom-
ing routine as indicated by the increase in the number 
of publications that incorporate data obtained in this 
way (a PubMed search returned 1637 articles published 
in 2004, 363 more than the previous year). For example, 
measuring the expression level of essentially every gene 
(including variant splice forms) starting with RNA from 
a small number of cells, or even a single cell, is possible 
because of advances in single-cell handling, RNA amplifi-
cation methods, and microarray technology. Microarrays, 
along with genomic sequence information and compu-
tational tools, facilitate the identification and classifica-
tion of DNA sequence information and allow scientists 
to understand the function and regulation of genome. 
This knowledge aids physicians and scientists in discover-
ing ways to prevent aberrant cellular processes and to 
improve human health.
cASe StudIeS
Metastatic Renal Cell Cancer
ND is a 53 year old male who presented to Jacobi 
Hospital with a 3 month history of left flank pain, gross 
hematuria, intermittent fever, and weight loss. On physi-
cal examination, he appeared pale. He was normoten-
sive with a temperature of 38ºC. He was found to have 
enlarged supraclavicular lymph nodes and a palpable 
mass in his left upper quadrant. Chest X-ray showed den-
sities in his left lung. Abdominal CT revealed a mass in his 
left kidney and enlarged retroperitoneal lymph nodes.
Laboratory findings included a white blood count (WBC) 
of 8.3x109 cells/L with a normal differential, a hemo-
globin (Hb) of 9.2 g/dL, and a hematocrit (Hct) of 26%. 
His serum calcium was 12.3 mg/dL. All other electrolytes 
were normal. Parathyroid hormone levels were elevated. 
Blood urea nitrogen (BUN) was 20 mg/dL and creatinine 
was 1.7 mg/dL. Urinalysis showed gross hematuria.
A diagnosis of stage IV metastatic renal cell cancer was 
made, and the patient underwent a left nephrectomy, 
with removal of adjacent metastases. Pathologic exami-
nation revealed clear cell histology. The patient was 
placed on a course of high dose interleukin-2, along 
with corticosteroids and calcitonin. Serum calcium levels 
returned to normal, and the patient felt better.
The patient was told of the poor prognosis for his condi-
tion and that it was characterized by a wide variability 
in the period of survival. His physician recommended a 
microarray study to answer this question. As a result, 
ND asked his physician to arrange for a gene-expression 
profile of the tumor. A study was conducted by research-
ers in the National Cancer Institute in 2003 (Vasselli et al., 
2003), who found the presence of two distinct patterns 
of gene expression in the primary tumors of patients 
with metastatic renal cancer. These patterns correlated 
with difference in survival between the patient groups. 
Among the genes identified in the study, vascular cell 
adhesion molecule-1 (VCAM-1) was identified as the 
most predictive gene for survival. This gene was uniform-
ly up-regulated in patients with longer survival (Vasselli 
et al., 2003). ND’s gene expression profile was consistent 
with a poor prognosis. ND died three years after he was 
diagnosed. 
Diffuse Large B-cell Lymphoma
AP is a 38 year old HIV positive male with a CD4+ T-cell 
count of 148 cells per cubic millimeter blood and a viral 
load of 477 copies/mL. He was admitted to Montefiore 
Medical Center with complaints of cough (productive of 
bloody sputum), low grade intermittent fever, weight 
loss, fatigue, and “swollen glands.” The patient first 
noted swollen glands in his femoral and inguinal areas 
approximately six weeks prior to admission. A chest X-ray 
demonstrated a right-sided pleural effusion and possible 
infiltrate. He was started on ceftriaxone. There is no past 
history of exposure to tuberculosis and sputum smears 
were found to be negative.
On physical exam several days after admission the hema-
tologists found maximum temperature (Tmax) of 101.3ºF, 
palpable small preauricular lymph nodes, bilateral high 
anterior cervical lymph nodes, bilateral supraclavicular 
lymph nodes along the clavicle, a small left axillary node, 
bilateral epitrochlear nodes, and bilateral large inguinal 
and femoral nodes. There was no tonsillar enlargement 
or splenomegaly.
Laboratory findings included a WBC of 5.9x109 cells/L 
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with a normal differential, a RBC of 14,000 cells/L, Hb 
of 8.5 grams/dL, a Hct of 21%, platelet count of 111x109 
cells/L, mean cell volume (MCV) of 82 fL, and red cell 
distribution width (RDW) of 17.1. Patient’s total protein 
was 7.1 g/L; albumin was 2.4 g/L; bilirubin, transami-
nases, alkaline phosphatase were normal, and lactate 
dehydrogenase (LDH) was 361 units/L. Serum iron was 
35 µmol/L, total iron-binding capacity (TIBC) was 169 
µmol/L, ferritin was 2640 µg/L, B12 was 264 pg/ml, and 
folate was 11.6 ng/ml. Pleural fluid pH was 7.157, LDH 
measured 1956 units/L. Renal function, thyroid function 
and artherial blood gasses were all normal. A complete 
blood count (CBC) performed 10 days prior to admission 
demonstrated a WBC of 4.5x109 cells/L, hemoglobin 13.4 
grams/dL, platelets 283x109 cells/L.
Examination of his peripheral blood smear demonstrated 
mild aniso- and poikilocytosis with increased reactive-
appearing monocytes. No platelet clumps were present. 
The patient underwent lymph node biopsy which dem-
onstrated a diffuse large cell non-Hodgkin’s lymphoma. 
He was further subtyped by immunohistochemistry and 
was found to have a B-cell lymphoma. Since only 40% 
of patients with large B-cell lymphoma respond well to 
therapy, his physician felt that AP would benefit from a 
recently developed microarray method for identifying 
this group of patients (Alizadeh et al., 2000). The authors 
of the study demonstrated a difference in gene expres-
sion among the tumors of diffuse large B-cell lymphoma 
patients, due to a variation in tumor proliferation rate 
and differentiation state, as well as host response. They 
identified two molecularly distinct forms of the disease 
whose gene expression patterns indicate different stages 
of B-cell differentiation. The first type expressed genes 
characteristic of germinal center B cells and the second 
type expressed genes induced during in vitro activation 
of peripheral blood B cells. Patients with germinal center 
expression pattern had a significantly better overall sur-
vival than the second group. Unfortunately, the results of 
the microarray test showed that AP had a tumor express-
ing genes induced during in vitro activation of periph-
eral blood B cells. Despite treatment, he died three years 
after being diagnosed.
Ductal Carcinoma of the Breast
 
MS is a 45 year old female. During routine clinical 
examination her physician discovered a nodule two cen-
timeters in diameter in the upper quadrant of the right 
breast. Retraction of the skin and nipple was present. A 
mammogram revealed a radiopacity with irregular mar-
gins. The echographic image demonstrated an area with 
irregular margins, suggestive of a breast carcinoma. The 
patient underwent right total mastectomy. The post-sur-
gical histological examination diagnosed infiltrating duc-
tal carcinoma, without metastasis. An endocrine therapy 
with tamoxifen was prescribed for the period of five 
years. The patient felt very anxious about the possibility 
of developing distant metastasis. In order to alleviate the 
anxiety her physician referred her to a study for prog-
nosis prediction based on DNA microarray technology. 
The authors applied DNA microarray analysis to primary 
breast tumors of 117 patients, and used supervised clas-
sification to identify a gene expression signature predic-
tive of metastases in patients without tumor cells in local 
lymph nodes at the time of diagnosis. In addition, they 
identified a signature that separates tumors of BRCA1 
carriers. The study concluded that women under 55 years 
of age diagnosed with lymph node-negative breast can-
cer have a poor prognosis if their tumors express a subset 
of genes regulating cell cycle, angiogenesis, invasion, 
and metastasis (van’t Veer et al., 2002). 
Acute Myelogenous Leukemia
A 66 year old man presented with one week of bruis-
ing and fatigue. No lymphadenopathy or splenomegaly 
were observed on physical examination. Laboratory 
studies showed WBC of 90,000 cells/L with 90% blasts, a 
Hb of 8.4 g/dL, a Hct of 25%, a platelet count of 8,500 
cells/L, and reticulocytes 0.5%. Blood smear showed 
many blasts, Auer rods, and marked thrombocytopenia. 
An examination of the bone marrow lead to a diagnosis 
of Acute Myelogenous Leukemia (AML). Further analysis 
demonstrated that blasts were present in the spinal fluid. 
Treatment was begun with daunorubicin and cytarabine, 
combined with intrathecal methotrexate twice weekly. 
After two identical courses of chemotherapy, bone mar-
row examination showed remission of the AML. An alter-
native to enzyme-based immunohistochemistry of bone 
marrow for distinction between AML and ALL (Acute 
Lymphoblastic Leukemia) is cancer classification based on 
gene expression profiles of acute leukemia patients. This 
method uses a microarray to examine the expression lev-
els of 50 genes and classify new patient samples as AML 
or ALL (Golub et al., 1999). 
dIScuSSIon
DNA microarrays are powerful tools for improving treat-
ment selection, diagnostic classification, and prognosis 
prediction. Since they offer a new and potentially better 
way for differentiating between tumor “types,” DNA 
microarrays have become tools for clinical oncologists. 
The main objective of these studies is to identify differen-
tially expressed genes, which characterize phenotypically 
defined groups. The goal of this comparison between 
classes is to develop a method for class prediction which 
would correctly identify the diagnosis, treatment, and 
prognosis of a patient based on gene expression data. 
Microarrays also offer the possibility for disease screen-
ing and prevention. For example, Dobrowolski and col-
leagues used DNA from blood samples to screen simul-
taneously for Factor V Leiden, sickle cell disease, and 
alpha-1-antitrypsin deficiency (Dobrowolski et al., 1999). 
This illustrates how microarrays can increase the number 
of early detected treatable diseases by development of 
new assays and consolidating existing ones. 
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DNA microarrays are already a standard laboratory tech-
nique for studying biological mechanisms, discovering 
new disease classification, and developing diagnostic 
tests. They are an integral tool for identifying new drug 
targets and advances in the field of pharmacogenomics. 
Although promising, microarray technology does not 
come without drawbacks. Practical problems include 
obtaining sufficient amounts (10ng-20µg RNA depend-
ing on the type of microarray) and appropriate speci-
mens. For example, heterogeneity of samples such as 
kidney which consists of numerous cell types (podocyte, 
endothelial, tubular, and mesangial cells) complicates 
the studies of cell-specific changes in gene expression. 
Another issue is the data analysis problem. Microarrays 
provide copious amounts of data points. While there 
is no doubt that microarrays are part of the future of 
clinical research and disease treatment, there is a clear 
need for careful study design and statistical analysis. 
Explication of the biologic basis of disease and devel-
opment of effective therapies will increasingly require 
interdisciplinary teams of biologists, computer scientists, 
and statisticians working together in a large scale col-
laborative manner.
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